Expert Interview
Evaluating the Market Potential of Eculizumab As A Treatment For Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Ticker(s): ALXNAn ophthalmologist/neurologist with experience treating NMOSD.
Please tell us about your clinical experience. How many patients do you currently treat with NMOSD
Added By: slingshot_insightsWhat % of your patients have anti-AQP4 auto antibody-positive NMOSD, and how different is the management of those patients
Added By: slingshot_insightsOut of 143 adult patients in the Phase 3 PREVENT trial, 97.9% of patients receiving Eculizumab were free of relapse compared to 63.2% on placebo at 48 weeks. How do you interpret this data?
Added By: slingshot_insightsHow important is relapse prevention in this disease, how do you prevent complement activation by anti-AQP4 auto-antibodies and what immuno suppressive therapy choices are most common
Added By: slingshot_insightsHow likely would you be to use Eculizumab as standalone therapy or in combination with immunosuppression, if approved
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
